Cargando…
14 Jahre HPV-Impfung: was haben wir erreicht?
Professor Harald zur Hausen, “father of human papillomavirus (HPV) vaccination” turned 85 years old this year. To mark the occasion, a retrospective look at the introduction of HPV vaccination 14 years ago is presented, highlighting the resistance that accompanied the early years of this beneficial...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512599/ https://www.ncbi.nlm.nih.gov/pubmed/34658401 http://dx.doi.org/10.1007/s00129-021-04869-3 |
_version_ | 1784583033380143104 |
---|---|
author | Wojcinski, Michael |
author_facet | Wojcinski, Michael |
author_sort | Wojcinski, Michael |
collection | PubMed |
description | Professor Harald zur Hausen, “father of human papillomavirus (HPV) vaccination” turned 85 years old this year. To mark the occasion, a retrospective look at the introduction of HPV vaccination 14 years ago is presented, highlighting the resistance that accompanied the early years of this beneficial vaccination. Even from an early stage vaccination for girls was included in the standard vaccination program of the Standing Commission on Vaccination (STIKO) in 2007 but it was not until 11 years later that it was recommended for boys as well. At around 50%, vaccination rates in both groups in Germany remain too low compared with other countries with school vaccination programs. Yet there are no longer any scientific doubts about HPV vaccination, which has been shown to be safe and effective in studies worldwide. Not only the reduction of precancerous lesions but also of cervical cancers could be shown in real-life studies in addition to the strong reduction of cases of condylomata acuminata in the vaccinated individuals, which is why the World Health Organization (WHO) has declared the elimination of cervical cancer by building population immunity as a vaccination goal. To this end, further efforts should be made to increase vaccination rates in Germany, which was also included in a corresponding appeal at the Conference of Health Ministers in June 2021. |
format | Online Article Text |
id | pubmed-8512599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-85125992021-10-13 14 Jahre HPV-Impfung: was haben wir erreicht? Wojcinski, Michael Gynakologe Leitthema Professor Harald zur Hausen, “father of human papillomavirus (HPV) vaccination” turned 85 years old this year. To mark the occasion, a retrospective look at the introduction of HPV vaccination 14 years ago is presented, highlighting the resistance that accompanied the early years of this beneficial vaccination. Even from an early stage vaccination for girls was included in the standard vaccination program of the Standing Commission on Vaccination (STIKO) in 2007 but it was not until 11 years later that it was recommended for boys as well. At around 50%, vaccination rates in both groups in Germany remain too low compared with other countries with school vaccination programs. Yet there are no longer any scientific doubts about HPV vaccination, which has been shown to be safe and effective in studies worldwide. Not only the reduction of precancerous lesions but also of cervical cancers could be shown in real-life studies in addition to the strong reduction of cases of condylomata acuminata in the vaccinated individuals, which is why the World Health Organization (WHO) has declared the elimination of cervical cancer by building population immunity as a vaccination goal. To this end, further efforts should be made to increase vaccination rates in Germany, which was also included in a corresponding appeal at the Conference of Health Ministers in June 2021. Springer Medizin 2021-10-13 2021 /pmc/articles/PMC8512599/ /pubmed/34658401 http://dx.doi.org/10.1007/s00129-021-04869-3 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Leitthema Wojcinski, Michael 14 Jahre HPV-Impfung: was haben wir erreicht? |
title | 14 Jahre HPV-Impfung: was haben wir erreicht? |
title_full | 14 Jahre HPV-Impfung: was haben wir erreicht? |
title_fullStr | 14 Jahre HPV-Impfung: was haben wir erreicht? |
title_full_unstemmed | 14 Jahre HPV-Impfung: was haben wir erreicht? |
title_short | 14 Jahre HPV-Impfung: was haben wir erreicht? |
title_sort | 14 jahre hpv-impfung: was haben wir erreicht? |
topic | Leitthema |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512599/ https://www.ncbi.nlm.nih.gov/pubmed/34658401 http://dx.doi.org/10.1007/s00129-021-04869-3 |
work_keys_str_mv | AT wojcinskimichael 14jahrehpvimpfungwashabenwirerreicht |